Screening mammography use and chemotherapy among female stage II colon cancer patients: a retrospective cohort study.
BACKGROUND
Although chemotherapy is not a routine recommendation for stage II colon cancer by the U.S. national guidelines, 20-30% of patients have received chemotherapy. This study investigated whether screening mammography use before the cancer diagnosis was associated with chemotherapy use among female elderly patients with stage II colon cancer.


METHODS
Retrospective cohort study on 2910 female stage II colon cancer patients aged 67-79 using the Surveillance, Epidemiology and End Results (SEER)-Medicare data (1996-2002). Screening mammography use and chemotherapy use were identified using Medicare claims data. Multivariate logistic regression and Kaplan-Meier curves were used.


RESULTS
About 25% of female elderly patients received chemotherapy. The chemotherapy rates increased from 22% in 1996-1998 to 26% in 2001-2002. After adjusting for socio-demographic variables, tumor characteristics and Charlson index for comorbidities, the odds of receiving chemotherapy were 28% higher among those who had a screening mammogram before the cancer diagnosis than those who did not (OR: 1.28, 95% CI: 1.07-1.54). Those with a prior mammogram also received chemotherapy earlier than those without. In addition, patients with unfavorable tumor characteristics were more likely to receive chemotherapy. Mammography use before the cancer diagnosis was associated with favorable tumor characteristics.


CONCLUSIONS
Despite the controversy about the chemotherapy use among stage II colon cancer, female elderly patients still received chemotherapy at a high rate. Our findings suggest that patient's health beliefs and health care seeking behavior, together with physician's recommendation, play important roles in the cancer treatment decision.
Yu
Xinhua
X
Public Health Program, College of Osteopathic Medicine, Health Professions Division, Nova Southeastern University, Fort Lauderdale, FL, USA. xinhua.yu@nova.edu
McBean
Alexander M
AM
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D016015:Logistic Models; D008327:Mammography / Q000706:statistics & numerical data*; D008403:Mass Screening / Q000706:statistics & numerical data*; D009367:Neoplasm Staging; D010342:Patient Acceptance of Health Care; D012189:Retrospective Studies; D012959:Socioeconomic Factors
D000970:Antineoplastic Agents
Int J Canc Prev. 2005 May;2(3):169-179
19122776
N Engl J Med. 2001 Oct 11;345(15):1091-7
11596588
J Clin Epidemiol. 1992 Jun;45(6):613-9
1607900
Med Care. 2002 Aug;40(8 Suppl):IV-3-18
12187163
J Behav Med. 1994 Aug;17(4):391-406
7966260
Am J Med. 2005 Oct;118(10):1078-86
16194635
Acad Radiol. 2005 Apr;12(4):451-8
15831418
Lancet. 2007 Dec 15;370(9604):2020-9
18083404
J Clin Oncol. 2006 May 20;24(15):2368-75
16618946
Am J Gastroenterol. 2003 Aug;98(8):1875-80
12907347
J Natl Cancer Inst. 2001 Jun 6;93(11):850-7
11390534
Med Care. 2006 Oct;44(10):921-8
17001263
JAMA. 2007 Nov 14;298(18):2149-54
18000198
J Chronic Dis. 1987;40(5):373-83
3558716
Cancer. 2006 Dec 1;107(11):2581-8
17078055
Womens Health Issues. 2005 Nov-Dec;15(6):249-57
16325138
J Clin Oncol. 2002 Oct 1;20(19):3999-4005
12351597
J Natl Cancer Inst. 2006 May 3;98(9):610-9
16670386
J Clin Oncol. 2004 Aug 15;22(16):3408-19
15199089
J Cancer Surviv. 2007 Dec;1(4):275-82
18648962
Int J Colorectal Dis. 2007 Aug;22(8):887-95
17235506
Am J Obstet Gynecol. 2008 Jan;198(1):86.e1-8
18166316
Med Care. 2002 Aug;40(8 Suppl):IV-55-61
12187169